• Je něco špatně v tomto záznamu ?

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response

D. Reimer, M. Boesch, D. Wolf, C. Marth, S. Sopper, J. Hatina, P. Altevogt, W. Parson, H. Hackl, AG. Zeimet,

. 2018 ; 142 (8) : 1640-1651. [pub] 20171214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001058

Vav3 is a key modulator of GTP-hydrolases of the Rho/Rac family, which are crucially involved in cell proliferation. Vav3 is alternatively spliced in full-length Vav3-alpha and N-terminal truncated Vav3.1 lacking its self-regulatory domains. The aim of our study was to estimate the clinical impact of Vav3 and all other Vav family members in ovarian cancer. Purification of a stem-cell like side-population (SP) from ovarian cancer cell lines was performed by flow cytometry/FACS. Differences in gene expression between SP and NSP were assessed by Gene Array analysis and confirmed by RT-PCR and immunoblot. In addition, Vav mRNA expression was determined in 150 epithelial ovarian cancers. Clinicopathological parameters, platinum-sensitivity and survival were analyzed and associated with Vav expression. SP fractions of ovarian cancer cell lines exhibited marked overexpression of Vav3.1 (p < 0.001). Vav1 and Vav2 did not prove to be of clinicopathologic relevance in ovarian cancer. High Vav3.1 expression correlated with higher FIGO stage and residual disease. Furthermore, Vav3.1 overexpression was associated with poor progression-free (HR = 2.820, p = 0.0001) and overall survival (HR = 2.842, p = 0.0001). Subgroup analyses revealed an impact of Vav3.1 on survival in Type-II but not in Type-I cancers. Notably, platinum-refractory cancers showed marked overexpression of Vav3.1 compared to other subsets of platinum-sensitivity (15.848 vs. 6.653, p = 0.0001). In conclusion, Vav3.1 is over-expressed in stem-cell like SP fractions and is clinically relevant in the pathophysiology of ovarian cancer. The N-terminal truncated Vav3.1 may be decisively involved in mechanisms causing genuine multi-drug resistance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001058
003      
CZ-PrNML
005      
20190121101214.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.31186 $2 doi
035    __
$a (PubMed)29194596
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Reimer, Daniel $u Department of Obstetrics and Gynecology, Medical University Innsbruck, 6020, Innsbruck, Austria.
245    10
$a Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response / $c D. Reimer, M. Boesch, D. Wolf, C. Marth, S. Sopper, J. Hatina, P. Altevogt, W. Parson, H. Hackl, AG. Zeimet,
520    9_
$a Vav3 is a key modulator of GTP-hydrolases of the Rho/Rac family, which are crucially involved in cell proliferation. Vav3 is alternatively spliced in full-length Vav3-alpha and N-terminal truncated Vav3.1 lacking its self-regulatory domains. The aim of our study was to estimate the clinical impact of Vav3 and all other Vav family members in ovarian cancer. Purification of a stem-cell like side-population (SP) from ovarian cancer cell lines was performed by flow cytometry/FACS. Differences in gene expression between SP and NSP were assessed by Gene Array analysis and confirmed by RT-PCR and immunoblot. In addition, Vav mRNA expression was determined in 150 epithelial ovarian cancers. Clinicopathological parameters, platinum-sensitivity and survival were analyzed and associated with Vav expression. SP fractions of ovarian cancer cell lines exhibited marked overexpression of Vav3.1 (p < 0.001). Vav1 and Vav2 did not prove to be of clinicopathologic relevance in ovarian cancer. High Vav3.1 expression correlated with higher FIGO stage and residual disease. Furthermore, Vav3.1 overexpression was associated with poor progression-free (HR = 2.820, p = 0.0001) and overall survival (HR = 2.842, p = 0.0001). Subgroup analyses revealed an impact of Vav3.1 on survival in Type-II but not in Type-I cancers. Notably, platinum-refractory cancers showed marked overexpression of Vav3.1 compared to other subsets of platinum-sensitivity (15.848 vs. 6.653, p = 0.0001). In conclusion, Vav3.1 is over-expressed in stem-cell like SP fractions and is clinically relevant in the pathophysiology of ovarian cancer. The N-terminal truncated Vav3.1 may be decisively involved in mechanisms causing genuine multi-drug resistance.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové kmenové buňky $x účinky léků $x metabolismus $7 D014411
650    _2
$a organoplatinové sloučeniny $x terapeutické užití $7 D009944
650    _2
$a nádory vaječníků $x farmakoterapie $x genetika $x metabolismus $7 D010051
650    _2
$a fosforylace $x účinky léků $7 D010766
650    _2
$a prognóza $7 D011379
650    _2
$a protein - isoformy $x metabolismus $7 D020033
650    _2
$a protoonkogenní proteiny c-vav $x metabolismus $7 D051567
650    _2
$a messenger RNA $x metabolismus $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Boesch, Maximilian $u Institute of Immunobiology, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland. Internal Medicine V, Innsbruck Medical University, 6020, Innsbruck, Austria. Tyrolean Cancer Research Institute, 6020, Innsbruck, Austria.
700    1_
$a Wolf, Dominik $u Internal Medicine V, Innsbruck Medical University, 6020, Innsbruck, Austria. Medical Clinic 3, Oncology, Hematology, Immunology and Rheumatology, University Clinic Bonn (UKB), 53127, Bonn, Germany.
700    1_
$a Marth, Christian $u Department of Obstetrics and Gynecology, Medical University Innsbruck, 6020, Innsbruck, Austria.
700    1_
$a Sopper, Sieghart $u Internal Medicine V, Innsbruck Medical University, 6020, Innsbruck, Austria. Tyrolean Cancer Research Institute, 6020, Innsbruck, Austria.
700    1_
$a Hatina, Jiri $u Department of Biology and Biomedical Centre, Faculty of Medicine Pilsen, Charles University Prague, 30100, Pilsen, Czech Republic.
700    1_
$a Altevogt, Peter $u Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167, Mannheim, Germany.
700    1_
$a Parson, Walther $u Institute of Legal Medicine, Medical University Innsbruck, 6020, Innsbruck, Austria.
700    1_
$a Hackl, Hubert $u Division of Bioinformatics, Biocenter, Medical University Innsbruck, 6020, Innsbruck, Austria.
700    1_
$a Zeimet, Alain G $u Department of Obstetrics and Gynecology, Medical University Innsbruck, 6020, Innsbruck, Austria.
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 142, č. 8 (2018), s. 1640-1651
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29194596 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190121101433 $b ABA008
999    __
$a ok $b bmc $g 1363986 $s 1039181
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 142 $c 8 $d 1640-1651 $e 20171214 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace